NCT07842926Recruiting
Acute Effects of Capacitive-Resistive Radiofrequency Therapy in People With Parkinson's Disease
Safety, Tolerability, and Acute Effects of Capacitive-Resistive Radiofrequency Therapy (TECAR) Applied to the Lower Limbs in People With Parkinson's Disease: An Experimental Within-Subject Study
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
This study will investigate the immediate and short-term effects of capacitive-resistive radiofrequency therapy (TECAR) applied to the lower limbs in people with Parkinson's disease. The main aim is to determine which of four different TECAR application protocols produces the greatest improvement in muscle stiffness and walking function. Twenty participants with Parkinson's disease will receive four different TECAR protocols in four separate sessions. The protocols will include capacitive treatment, resistive treatment, and two combinations of capacitive and resistive treatment. Each participant will receive all four protocols, and the order in which they are applied will be randomized. Sessions will be separated by a 7-day washout period. Muscle stiffness will be measured using the MyotonPRO device. Walking and functional mobility will also be assessed using the Timed Up and Go test and the 10-Metre Walk Test. Joint range of motion and lower-limb musculoskeletal pain will also be evaluated. Measurements will be performed immediately before treatment, immediately after treatment, and 48 hours after each session. The study will also record any discomfort or adverse events associated with TECAR therapy to evaluate the safety and tolerability of the different treatment protocols.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 21 Sept 2026
- Start date
- 21 Sept 2026
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Universidad San Jorge
- Diseases
- Parkinson disease
- NCT number
- NCT07842926
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 21 Sept 2026 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Advanced Parkinson's disease, defined as Hoehn and Yahr stage \>III, with severe postural instability.
- Other neurological or musculoskeletal conditions that could interfere with the assessment of lower-limb rigidity or gait.
- Skin lesions, open wounds, or infection in the area where radiofrequency therapy will be applied.
- Presence of a pacemaker, defibrillator, other implanted electronic device, or another contraindication to TECAR therapy, such as altered thermal sensitivity.
- Lower-limb surgery within the previous 6 months.
Who the study is looking for
- Age between 55 and 90 years. Clinical diagnosis of idiopathic Parkinson's disease confirmed by a Neurology specialist.
- Hoehn and Yahr stage II or III. Functional walking ability. Clinically relevant lower-limb rigidity in at least one leg, defined as a score ≥2 on item 3.3d (right lower limb) or 3.3e (left lower limb) of Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
- Stable antiparkinsonian pharmacological treatment during the previous 4 weeks, with no planned changes during the intervention period.
- Ability to understand and follow simple instructions, defined as a score \>24 on the validated Spanish version of the Mini-Mental State Examination (MMSE-MEC).
- Provision of written informed consent.
Age in the registry: 55 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Asociación Parkinson Aragón Coordinator of this site? Confirm its status | Zaragoza | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.